Loading company…
Photys Therapeutics develops small molecule medicines that modulate protein phosphorylation.
Founded in 2021 and based in Massachusetts, Photys Therapeutics develops phosphorylation-inducing chimeric small molecule medicines, or PHICS, for cancer, immune, metabolic, and rare diseases. Its platform targets disease proteins and aims to restore protein function. In September 2022, it raised 75 million in Series A funding led by MPM Capital, with Omega Funds, Longwood fund, 8VC, Arkin Holdings, Mass General Brigham Ventures, MRL Ventures Fund, Merck Ventures, Eli Lilly and Company, and Heritage Medical Systems participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in